Loading...
Docoh

Glaukos (GKOS)

Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Company profile

Ticker
GKOS
Exchange
Website
CEO
Thomas Burns
Employees
Incorporated
Location
Fiscal year end
Former names
GLAUKOS CORP
SEC CIK
Subsidiaries
Glaukos Germany GmbH • Glaukos Australia Pty Ltd • Glaukos Canada Inc. • Glaukos France SAS • Glaukos Ireland Limited • Glaukos Netherlands B.V. • Glaukos Produtos Médicos Ltda. • Glaukos Sweden AB • Glaukos UK Limited • Glaukos Singapore PTE. LTD. ...

GKOS stock data

Analyst ratings and price targets

Last 3 months

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

4 Aug 22
2 Oct 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 111.68M 111.68M 111.68M 111.68M 111.68M 111.68M
Cash burn (monthly) 1.31M 1.34M 15.21M 3.92M 4.07M (no burn)
Cash used (since last report) 4.07M 4.14M 47.2M 12.17M 12.62M n/a
Cash remaining 107.61M 107.54M 64.49M 99.52M 99.06M n/a
Runway (months of cash) 82.0 80.5 4.2 25.4 24.3 n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Aug 22 Kliman Gilbert H Common Stock Other Acquire J Yes No 0 2,382 0 16,347
19 Aug 22 Kliman Gilbert H Common Stock Other Dispose J No No 0 2,382 0 24,923
5 Aug 22 Kliman Gilbert H Common Stock Sell Dispose S Yes No 53.0129 3,362 178.23K 0
4 Aug 22 Kliman Gilbert H Common Stock Other Acquire J No No 0 19,045 0 27,305
4 Aug 22 Kliman Gilbert H Common Stock Other Dispose J Yes No 0 83,955 0 0
4 Aug 22 Kliman Gilbert H Common Stock Other Acquire J Yes No 0 83,955 0 83,955
4 Aug 22 Kliman Gilbert H Common Stock Other Dispose J Yes No 0 333,917 0 0
2 Jun 22 Kliman Gilbert H Common Stock Grant Acquire A No No 0 4,364 0 8,260
2 Jun 22 Stapley Marc Common Stock Grant Acquire A No No 0 4,364 0 26,186
2 Jun 22 Denice Torres Common Stock Grant Acquire A No No 0 4,364 0 11,729
13F holders Current Prev Q Change
Total holders 199 215 -7.4%
Opened positions 21 33 -36.4%
Closed positions 37 26 +42.3%
Increased positions 68 73 -6.8%
Reduced positions 74 74
13F shares Current Prev Q Change
Total value 2.06B 2.55B -19.1%
Total shares 49.1M 48.14M +2.0%
Total puts 321.5K 479K -32.9%
Total calls 157.9K 568.9K -72.2%
Total put/call ratio 2.0 0.8 +141.8%
Largest owners Shares Value Change
BLK Blackrock 7.52M $341.72M +0.8%
Vanguard 5.36M $243.33M +2.7%
Wellington Management 4.42M $200.9M -5.9%
Flynn James E 3.34M $0 0.0%
Brown Capital Management 2.65M $120.37M -7.6%
Alger Associates 2.02M $74.09M 0.0%
Artisan Partners Limited Partnership 1.96M $89.12M -0.4%
JHG Janus Henderson 1.87M $84.99M +0.1%
STT State Street 1.7M $77.14M +1.0%
Point72 Asset Management 1.32M $60.04M +13.8%
Largest transactions Shares Bought/sold Change
Pura Vida Investments 796.6K +796.6K NEW
Assenagon Asset Management 900.11K +753.35K +513.3%
Deerfield Management 1.04M +670K +181.3%
Millennium Management 118.94K -638.89K -84.3%
BCS Barclays 39.11K -616.81K -94.0%
Balyasny Asset Management 487.89K +476.27K +4099.4%
Polar Asset Management Partners 268.11K -306.8K -53.4%
Wellington Management 4.42M -276.78K -5.9%
Brown Capital Management 2.65M -219.35K -7.6%
Point72 Asset Management 1.32M +160.35K +13.8%

Financial report summary

?
Management Discussion
  • Net sales for the three months ended June 30, 2022 and June 30, 2021 were $72.7 million and $78.1 million, respectively.
  • Net sales of glaucoma products in the United States were $38.2 million and $46.3 million for the three months ended June 30, 2022 and June 30, 2021, respectively, decreasing by 18% . This decrease is primarily due to lower volumes caused by the reduced CMS physician fee that was implemented on January 1, 2022, which has disrupted
  • traditional customer ordering patterns and has resulted in our customers’ trialing of competitive products. Additionally, sales in the second quarter 2021 were positively impacted by abnormally high demand for cataract and glaucoma procedures following the rollout of the COVID-19 vaccines and increasing normalized economic and operating conditions within certain markets in which we operated at that time.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: abnormally, adult, chemical, commerce, exceeded, inflationary, iVeena, macroeconomic, rare, reopened, retention, speaker, talent, turnover, variance, workplace
Removed: asymptomatic, authorized, carefully, closure, deferral, disguised, forward, impersonation, inclusion, infection, monitoring, notably, onsite, predicted, progression, protective, relocate, saving, shifted, trajectory, trend